Gang L Liu

US Patent:

8497637, Jul 30, 2013

Filed:

Apr 13, 2011

Appl. No.:

13/066388

Inventors:

Gang Gary Liu - Plano TX, US

International Classification:

H05B 37/02
H05B 39/04
H05B 41/36
F02P 3/08

US Classification:

315225, 315209 CD, 315172

Abstract:

A constant voltage dimmable LED (Light Emitting Diode) driver is disclosed that is compatible with all types of dimmers, including conventional phase cut (TRIAC) dimmers, and behaves like a conventional constant voltage driver which can be connected to any size of LED load that has a matching voltage rating. The driver produces a continuous train of pulses for driving the LED load and obtains an averaged measure of the voltage at the AC input for controlling the duty cycle of the continuous train of pulses. Therefore, when the averaged measure of the voltage at the AC input is reduced by a dimmer, the duty cycle reduces, resulting in a dimmed LED. The driver can be created by adding a few components to a conventional wide input range AC-DC converter without or with very little modifications.

US Patent:

20130300303, Nov 14, 2013

Filed:

Jul 17, 2013

Appl. No.:

13/944611

Inventors:

Gang Gary Liu - Plano TX, US

International Classification:

H05B 33/08

US Classification:

315200 R

Abstract:

A constant voltage dimmable LED (Light Emitting Diode) driver is disclosed that is compatible with all types of dimmers, including conventional phase cut (TRIAC) dimmers, and behaves like a conventional constant voltage driver which can be connected to any size of LED load that has a matching voltage rating. The driver produces a continuous train of pulses for driving the LED load and obtains an averaged measure of the voltage at the AC input for controlling the duty cycle of the continuous train of pulses. Therefore, when the averaged measure of the voltage at the AC input is reduced by a dimmer, the duty cycle reduces, resulting in a dimmed LED. The driver can be created by adding a few components to a conventional wide input range AC-DC converter without or with very little modifications.

US Patent:

20140057914, Feb 27, 2014

Filed:

Aug 23, 2013

Appl. No.:

13/974261

Inventors:

Maria Emilia DiFrancesco - Houston TX, US
Alessia Petrocchi - Houston TX, US
Joe Marszalek - Houston TX, US
Gang Liu - Houston TX, US

Assignee:

Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center - Houston TX

International Classification:

C07D 413/04
A61K 31/496
A61K 45/06
C07D 413/14
A61K 31/5377
A61K 31/454
A61K 31/4245
C07D 417/04

US Classification:

5142362, 514364, 548131, 51425402, 544369, 51425403, 544364, 5142531, 544138, 546209, 514326

Abstract:

The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.

US Patent:

20140073634, Mar 13, 2014

Filed:

Aug 23, 2013

Appl. No.:

13/974266

Inventors:

Maria Emilia DiFrancesco - Houston TX, US
Alessia Petrocchi - Houston TX, US
Joe Marszalek - Houston TX, US
Gang Liu - Houston TX, US
Zhijun Kang - Houston TX, US
Chris Carroll - Houston TX, US
Timothy McAfoos - Houston TX, US
Barbara Czako - Houston TX, US

Assignee:

Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center - Houston TX

International Classification:

C07D 417/14
A61K 31/501
C07D 413/14
C07D 401/06
C07D 237/24
A61K 31/541
C07D 413/04
C07D 213/82
A61K 31/5377
A61K 31/4545
A61K 31/444
A61K 31/4439
A61K 45/06
A61K 31/496

US Classification:

5142278, 51425202, 544238, 544364, 5142531, 51425312, 544114, 5142365, 546194, 514318, 546256, 514333, 544131, 5142362, 51425219, 544333, 5462694, 514340, 51425205, 544 582

Abstract:

The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.

US Patent:

20220267311, Aug 25, 2022

Filed:

Mar 10, 2022

Appl. No.:

17/654301

Inventors:

- Austin TX, US
Gang LIU - Sugar Land TX, US
Kang LE - Sugar Land TX, US
Jason CROSS - Pearland TX, US
Philip JONES - Houston TX, US

International Classification:

C07D 413/14
C07D 401/04
C07D 471/04
C07D 417/14
C07D 401/14
C07D 405/14

Abstract:

Disclosed herein are compounds which inhibit the kinase activity of dual leucine zipper (DLK) kinase (MAP3K12), pharmaceutical compositions, and methods of treatment of DLK-mediated diseases, such as neurological diseases that result from traumatic injury to central nervous system and peripheral nervous system neurons (e.g. stroke, traumatic brain injury, spinal cord injury), or that result from a chronic neurodegenerative condition (e.g. Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, progressive supranuclear palsy, Lewy body disease, Kennedy's disease, and other related conditions), from neuropathies resulting from neurological damage (chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and related conditions) and from cognitive disorders caused by pharmacological intervention (e.g. chemotherapy induced cognitive disorder, also known as chemobrain).

US Patent:

20210206745, Jul 8, 2021

Filed:

Dec 16, 2020

Appl. No.:

17/124051

Inventors:

- Austin TX, US
Michael J. SOTH - Sugar Land TX, US
Jason P. BURKE - Houston TX, US
Kang LE - Sugar Land TX, US
Gang LIU - Sugar Land TX, US

International Classification:

C07D 401/14
A61K 31/501
A61K 45/06
A61P 35/00
A61K 31/337

Abstract:

Disclosed herein is the compound (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide, and salt forms and polymorphs thereof demonstrating improved exposure after oral dosing. Methods of inhibition GLS1 activity in a human or animal subject are also provided.

US Patent:

20200407353, Dec 31, 2020

Filed:

Jul 10, 2020

Appl. No.:

16/925974

Inventors:

- Austin TX, US
Philip JONES - Houston TX, US
Timothy HEFFERNAN - Sugar Land TX, US
Matthew M. HAMILTON - Missouri City TX, US
Zhijun KANG - Richmond TX, US
Michael J. SOTH - Sugar Land TX, US
Jason P. BURKE - Houston TX, US
Kang LE - Sugar Land TX, US
Christopher Lawrence CARROLL - Houston TX, US
Wylie S. PALMER - Houston TX, US
Richard LEWIS - Missouri City TX, US
Timothy MCAFOOS - Pearland TX, US
Barbara CZAKO - Bellaire TX, US
Gang LIU - Sugar Land TX, US
Jay THEROFF - Manvel TX, US
Zachary HERRERA - El Cerrito CA, US
Anne YAU - Houston TX, US

International Classification:

C07D 417/14
A61K 31/4439
A61K 45/06
C07D 417/06
A61K 31/433
C07D 403/06
A61K 31/501
C07D 401/14
A61K 31/454
A61K 31/4192
C07D 405/14
C07D 403/14
A61K 31/444
C07D 493/08
A61K 31/497

Abstract:

Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I:Methods of inhibition GLS1 activity in a human or animal subject are also provided.

US Patent:

20190308978, Oct 10, 2019

Filed:

Apr 8, 2019

Appl. No.:

16/378309

Inventors:

- Austin TX, US
Michael J. SOTH - Sugar Land TX, US
Gang LIU - Sugar Land TX, US
Philip JONES - Houston TX, US
Jason Bryant CROSS - Pearland TX, US
Timothy Joseph MCAFOOS - Pearland TX, US
Christopher L. CARROLL - Houston TX, US
Richard T. LEWIS - Missouri City TX, US

International Classification:

C07D 487/04
C07D 519/00

Abstract:

The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.